RX-DX Deals in Coagulation Monitoring
In the past, diagnostic companies may have been eager to tap the vast resources of pharmaceutical companies, but the feeling wasn't mutual. The few diagnostics companies that did get involved in such relationships tended to walk away dissatisfied with the attention being paid to them by pharmaceutical partners preoccupied with higher margin opportunities.
You may also be interested in...
Effective medical device regulation supports both safety and innovation needs. This article assesses how well the US FDA and the Australian TGA achieve this balance.
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.